Parabilis Medicines, Inc.
PBLS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$818.68M
Close$
$-15.32
154.1% downside
Current Fair Value
154.1% downsideOvervalued by 154.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $818.68 Million |
|---|---|
| Enterprise Value | $-210,494,595.00 |
| Earnings per Share | $-92.4 |
| Beta | 5.03 |
| Outstanding Shares | 28,908,277 |
Return
| Return on Equity | -16.31% |
|---|---|
| Return on Assets | -14.54% |
| Return on Invested Capital | -15.44% |
Valuation & Multiples
| P/E Ratio | -0.77 |
|---|---|
| PEG | -1.51 |
| Price to Sales | - |
| Price to Book Ratio | 0.79 |
| Enterprise Value to Revenue | 16381.79 |
| Enterprise Value to EBIT | -14.12 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.17
Consensus analyst estimateRevenue Estimate
$16.67 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.40
Consensus analyst estimateRevenue Estimate
$375,000
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 342.32% |
|---|---|
| Total Invested | $279,335▼ 99.99% |
| Investors Holding | 7▼ 73.00% |
About Parabilis Medicines, Inc.
145 employees
CEO: Mathai Mammen
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize t...